Ian A J Lorimer
Overview
Explore the profile of Ian A J Lorimer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
745
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lorimer I
Neurooncol Adv
. 2024 Apr;
6(1):vdae012.
PMID: 38616895
Glioblastoma is an aggressive and incurable brain cancer. This cancer establishes both local and systemic immunosuppression that creates a major obstacle to effective immunotherapies. Many studies point to tumor-resident myeloid...
2.
Lavictoire S, Jomaa D, Gont A, Jardine K, Cook D, Lorimer I
J Biol Chem
. 2021 Oct;
297(5):101172.
PMID: 34624316
The protein Lgl1 is a key regulator of cell polarity. We previously showed that Lgl1 is inactivated by hyperphosphorylation in glioblastoma as a consequence of PTEN tumour suppressor loss and...
3.
Jacques F, Nicholas G, Lorimer I, Sikati Foko V, Prevost J, Dumais N, et al.
Neurooncol Adv
. 2021 Oct;
3(1):vdab118.
PMID: 34604752
Background: Glioblastoma (GBM) is known to use both local and systemic immunosuppressive strategies. One such strategy is the expression of the immune checkpoint protein programmed cell death ligand-1 (PD-L1) by...
4.
Ramanathan A, Lorimer I
Cancer Gene Ther
. 2021 Mar;
29(2):156-166.
PMID: 33753869
In spite of significant recent advances in our understanding of the genetics and cell biology of glioblastoma, to date, this has not led to improved treatments for this cancer. In...
5.
Lavictoire S, Gont A, Julian L, Stanford W, Vlasschaert C, Gray D, et al.
Mol Ther Methods Clin Dev
. 2017 Dec;
9:12-22.
PMID: 29255742
The tumor suppressor is frequently inactivated in glioblastoma. PTEN-L is a long form of PTEN produced by translation from an alternate upstream start codon. Unlike PTEN, PTEN-L has a signal...
6.
Kumar R, Gont A, Perkins T, Hanson J, Lorimer I
Sci Rep
. 2017 May;
7(1):2156.
PMID: 28526854
Glioblastoma is the most common type of adult brain tumour and has a median survival after diagnosis of a little more than a year. Glioblastomas have a high frequency of...
7.
Gont A, Daneshmand M, Woulfe J, Lavictoire S, Lorimer I
Oncotarget
. 2017 Jan;
8(5):8559-8573.
PMID: 28051998
A defining feature of the brain cancer glioblastoma is its highly invasive nature. When glioblastoma cells are isolated from patients using serum free conditions, they accurately recapitulate this invasive behaviour...
8.
Jahani-Asl A, Yin H, Soleimani V, Haque T, Luchman H, Chang N, et al.
Nat Neurosci
. 2016 Apr;
19(6):798-806.
PMID: 27110918
EGFRvIII-STAT3 signaling is important in glioblastoma pathogenesis. Here, we identified the cytokine receptor OSMR as a direct target gene of the transcription factor STAT3 in mouse astrocytes and human brain...
9.
Restall I, Parolin D, Daneshmand M, Hanson J, Simard M, Fitzpatrick M, et al.
Cell Cycle
. 2015 Jul;
14(18):2938-48.
PMID: 26208522
Cellular senescence is a tumor suppressor mechanism where cells enter a permanent growth arrest following cellular stress. Oncogene-induced senescence (OIS) is induced in non-malignant cells following the expression of an...
10.
Lorimer I
Curr Cancer Drug Targets
. 2015 Feb;
15(2):136-44.
PMID: 25643257
Glioblastoma (grade IV astrocytoma) is an aggressive and incurable form of brain tumor. It invariably shows extensive invasion at the time of diagnosis, often involving both hemispheres. Recent studies have...